Noninvasive measures of liver fibrosis

Authors

  • Don C. Rockey,

    Corresponding author
    1. Department of Medicine, and the Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX
    • University of Texas Southwestern Medical Center, Department of Internal Medicine, Division of Digestive and Liver Diseases, 5323 Harry Hines Blvd, Dallas, TX 75390-8887
    Search for more papers by this author
    • fax:214-648-0274.

  • D. Montgomery Bissell

    1. Department of Medicine, and the Division of Gastroenterology and Liver Center, University of California at San Francisco, San Francisco, CA
    Search for more papers by this author

  • Potential conflict of interest: Nothing to report.

Abstract

As novel therapies for liver fibrosis evolve, non-invasive measurement of liver fibrosis will be required to help manage patients with chronic liver disease. Although liver biopsy is the current and time-honored gold standard for measurement of liver fibrosis, it is poorly suited to frequent monitoring because of its expense and morbidity, and its accuracy suffers from sampling variation. At the current writing, serum markers and imaging methods are available and increasingly in use as alternatives to biopsy. However, many questions remain about their indications, accuracy, and cost-effectiveness, and more investigation is required before they are put into widespread use. The development of safe, inexpensive, and reliable noninvasive fibrosis measurement tools remains a research priority in clinical hepatology. (Hepatology 2006;43:S113–S120.)

Ancillary